288
ASSOCIATION FOR ACADEMIC SURGERY AND SOCIETY OF UNIVERSITY SURGEONS—ABSTRACTS
QS124. IS SERUM THYROGLOBULIN ACCURATE AS A PREOPERATIVE BIOMARKER OF MALIGNANCY IN FOLLICULAR AND HÜRTHLE-CELL NEOPLASMS OF THE THYROID? I. Suh, A. Griffin, W. T. Shen, Q. Y. Duh, O. H. Clark, E. Kebebew; University of California, San Francisco, San Francisco, CA QS125. -------------WITHDRAWN------------QS126. CYCLIN A1 IS EXPRESSED IN PARATHYROID ADENOMAS AND CORELLATES WITH PTH GENE EXPRESSION AND SERUM PTH. M. Abdelgadir Adam1, B. R. Untch1, D. Dixit2, S. Lampert1, H. Dressman2, J. Koh1, J. A. Olson, Jr.1; 1Deparment of Surgery, Duke University Medical Center, Durham, NC; 2Institute for Genome Sciences and Policy, Duke University, Durham, NC QS127. FOLLICULAR THYROID CANCER CELL GROWTH SUPPRESSION BY MG132, A PROTEOSOME INHIBITOR. S. J. Stoll, S. C. Pitt, H. Chen; University of Wisconsin, Madison, WI QS128. INHIBITION OF GROWTH IN MEDULLARY THYROID CANCER CELLS WITH HISTONE DEACETYLASE INHIBITORS AND LITHIUM CHLORIDE. J. T. Adler, D. G. Hottinger, M. Kunnimalaiyaan, H. Chen; University of Wisconsin, Madison, WI QS129. SODIUM BUTYRATE INHIBITS CELLULAR PROLIFERATION AND REDUCES ABERRANT HORMONE PRODUCTION IN PHEOCHROMOCYTOMA. M. A. Cayo, A. K. Cayo, S. Jarjour, H. Chen; University of Wisconsin, madison, WI QS130. MICRORNA MICROARRAY ANALYSIS OF HUMAN ADRENOCORTICAL TUMORS. P. S. Soon1, L. Tacon1, M. S. Sywak2, P. Campbell3, M. W. Yeh4, S. G. Wong5, R. Clifton-Bligh1, B. G. Robinson1, S. B. Sidhu1; 1Kolling Institute of Medical Research, St Leonards, Sydney, NSW, Australia; 2University of Sydney Endocrine Surgical Unit, St Leonards, Sydney, NSW, Australia; 3Department of Surgery, Liverpool and Bankstown Hospitals, Liverpool, Sydney, NSW, Australia; 4Endocrine Surgical Unit, University of California Los Angeles, Los Angeles, CA; 5Department of Medicine, Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, CA QS131. CURCUMIN ALTERS NEUROENDOCRINE PHENOTYPE AND SUPRESSESS CELL PROLIFERATION IN CARCINOID TUMOR CELLS. R. Jaskula-Sztul, M. Ndiaye, C. M. McManus, M. Landowski, H. Chen, M. Kunnimalaiyaan; University of Wisconsin, Madison, WI QS132. EXPRESSION OF NEURAL TRANSCRIPTION FACTORS IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS. T. Shida1, M. Furuya2, T. Kishimoto1, T. Tanizawa1, S. Takano1, F. Kimura1, H. Shimizu1, H. Yoshidome1, M. Ohtsuka1, T. Nikaido3, K. Koda4, Y. Nakatani1, M. Miyazaki1; 1Chiba University, Chiba, Japan; 2Yokohama City University, Yokohama, Japan; 3Jikey University, Tokyo, Japan; 4Teikyo University, Chiba, Japan QS133. HÜRTHLE CELL NEOPLASMS OF THE THYROID: A CONTEMPORARY SERIES. J. I. Lew, L. G. Koniaris, R. E. Montano, C. C. Solorzano; University of Miami Leonard M. Miller School of Medicine, Miami, FL QS134. LOCAL RECURRENCE OF ADRENOCORTICAL CARCINOMA AND THE ROLE OF ADJUVANT RADIATION
THERAPY. J. B. Ammori, G. Hammer, P. Gauger, G. Doherty, B. S. Miller; University of Michigan, Ann Arbor, MI QS135. IL13RA2 IS OVEREXPRESSED IN ADRENOCORTICAL CARCINOMA AND REGULATES CELL GROWTH. K. Menker, J. Weng, Q. Duh, O. Clark, E. Kebebew; UCSF, San Francisco, CA QS136. KIAA0101 IS OVEREXPRESSED IN ADRENOCORTICAL CARCINOMA AND REGULATES CELL GROWTH. N. Huynh, Q. Duh, O. Clark, E. Kebebew; UCSF, San Francisco, CA QS137. HAVE IMPROVEMENTS IN MEDICAL MANAGEMENT CHANGED THE PROFILES OF PATIENTS UNDERGOING PARATHYROIDECTOMY FOR SECONDARY HYPERPARATHYROIDISM? W. T. Shen, E. Kebebew, I. Suh, Q. Duh, O. H. Clark; UCSF/Mt. Zion Medical Center, San Francisco, CA QS138. THE FEV TRANSCRIPTION FACTOR IS ABBERANTLY EXPRESSED IN NEUROENDOCRINE TUMORS OF THE SMALL INTESTINE. Y. Wang, M. Zuraek, D. Donner, E. Bergsland, R. Warren, E. K. Nakakura; UC San Francisco, San Francisco, CA QS139. FAMILIAL PHEOCHROMOCYTOMA-A DISTINCT CLINICAL ENTITY WITH POSSIBLE GEOGRAPHIC VARIABILITY IN UNDERLYING GENETIC SYNDROMES. L. A. Adam1, J. R. Howe, V2, N. Gurll2, G. Lal2; 1University of Iowa, Iowa city, IA; 2University of Iowa, Iowa city, IA QS140. INCIDENTAL THYROID NODULES: WHAT IS THE LIKELIHOOD OF MALIGNANCY? M. Tallar, T. Yen, T. Wang, B. Krzywda, S. Wilson, S. G. Pappas; Medical College of Wisconsin, Milwaukee, WI
ONCOLOGY 11: IMMUNOLOGY QS141. CETUXIMAB COATED PANCREATIC CANCER CELLS INCREASE ACTIVITY OF IL-21 TREATED NK CELLS. K. D. Guenterberg, A. Tatum, S. V. Kondadasula, G. B. Lesinski, W. E. Carson, III; Ohio State University, Columbus, OH QS142. IMMUNO GENE THERAPY FOR LIVER METASTASIS BY SUBCUTANEOUS INJECTION OF ADENOVIRUS VECTOR EXPRESSING CD40 LIGAND IN RATS. T. Iida, H. Shiba, T. Misawa, T. Ohashi, Y. Eto, K. Yanaga; The Jikei University of Medicine, Tokyo, Japan QS143. INHIBITION OF PHOSPHATIDYLSERINE ON THE SURFACE OF TUMOR CELLS PROMOTES ANTI-TUMOR IMMUNITY AND SLOWS TUMOR GROWTH IN VIVO. M. Krein, C. Yin, J. Shilyansky; Carver College of Medicine, Iowa City, IA QS144. THE DAMAGE ASSOCIATED MOLECULAR PATTERN MOLECULE HMGB1 STIMULATES HEPATIC STELLATE CELL (HSC) ACTIVATION. X. Liang, A. Farkas, A. Romo de Vivar, M. T.Lotze, M. E. de Vera; University of Pittsburgh, Pittsburgh, PA QS145. TUMOR GROWTH KINETICS DETERMINE CANCERINDUCED IMMUNE SUPPRESSION. A. Russ, L. Wentworth, C. S. Cho; University of Wisconsin School of Medicine and Public Health, Madison, WI